In this study, we first evaluated the changes of circulating FGF21 in subjects with and without HP in T2DM patients, and we provided first clinical evidence showing that serum FGF21 levels were significantly increased in patients with T2DM than in healthy controls, and much higher FGF21 levels were observed in patients combined with HP. This evidence concerns the gene FGF21 and type 2 diabetes mellitus.